Loading
Life sciences · Journal article
Discover Chemistry. · August 4, 2026
Raises a question worth testing. It does not answer one.
This is a computational chemistry study using DFT calculations and ADMET prediction software to profile four halogenated quinoline derivatives as potential tuberculosis agents. No experimental synthesis, testing, or in vitro antimicrobial assay is reported; the findings are in silico predictions only and do not constitute evidence of biological activity.
Computational modelling study (in silico). Four halogenated aryl quinoline derivatives (QNL1, QNL2, QNL3, QNL4); no biological system or organism studied.. Intervention: Four derivatives of 1,4-dihydro-4-oxo-quinoline-3-carbohydrazide.
QNL1 and QNL3 derivatives predicted to have high intestinal absorption (>95%) and apparent permeability (Papp >1.0 × 10 cm/s) Oral bioavailability predicted at 0.55 for all four compounds Caco-2 intestinal permeability predicted between −4.708 and −4.756
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
No clinical or experimental evidence is presented. These computational predictions require validation through chemical synthesis, in vitro antimicrobial assays, and preclinical testing before any clinical relevance can be assessed.
Computational modelling of novel quinoline derivatives with no experimental biological validation; this is mechanistic and exploratory work that raises questions rather than answering them in a clinical or even in vitro experimental context.
As stated by the source record.
Quoted from the source exactly as published.
No clinical or experimental evidence is presented. These computational predictions require validation through chemical synthesis, in vitro antimicrobial assays, and preclinical testing before any clinical relevance can be assessed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Tuberculosis is caused by the bacterium Mycobacterium tuberculosis and is the leading cause of death from infectious diseases worldwide, being considered a granulomatous infection. The quinoline molecules were chosen because they possess antifungal and antimicrobial properties, which are normally related to their biological activities, being a privileged structure in medicinal chemistry, capable of modulating multiple targets, including kinases. The target prediction revealed a strong association with vascular endothelial growth factor receptor 2 (KDR), with 1300 and 1447 similar compounds. This article shows the structural reactivity of the four derivatives of 1,4-dihydro-4-oxo-quinoline-3-carbohydrazide, evaluated through DFT calculations in vacuum and DMSO (B3LYP/6–311 + + G(d,p)), using the ORCA 5.04 program. In addition, this study also used computational approaches of virtual screening and ADMET prediction to evaluate pharmacokinetic properties. The analyses were performed using the softwares SwissADME, ADMETlab 3.0, admetSAR 3.0, pkCSM, Pred-hERG 5.0, StopTox, and ADMET Prediction Service—LMC, and involved the evaluation of oral bioavailability (0.55 for all compounds), intestinal permeability (Caco-2: −4.708 to −4.756), toxicity (non-toxic), and pharmacokinetic profile, selecting the compounds with the best characteristics for absorption and distribution. The results showed that the QNL1 and QNL3 derivatives were the most favorable due to high intestinal absorption (> 95%) and apparent permeability (Papp > 1.0 × 10 cm/s), showing potential as a future drug. In summary, the findings show these compounds as promising candidates for the treatment of tuberculosis, E. coli bacteria, and the fungus Aspergillus fumigatus.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.